China Analyst Identifies 10 Pharma Stocks with Highest Growth Potential
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
type 2 diabetes
Cholesterol Drugs May Slow Diabetic Vision Loss, Study Finds
A large-scale study funded by the National Institutes of Health found that both blood sugar control and a combination of cholesterol-lowering lipid drugs were effective in slowing the progression of diabetic retinopathy.
Diabetes Drug Wins Approval, Helps the Competition
The approval of Novo Nordisk’s diabetes drug Victoza has led to an unintended benefit for a competitor.
Echo Therapeutics Rated Strong Spec Buy by Life Tech Capital
The significant differences between Echo Therapeutics’ Symphony system and the competition is the needle-free transdermal biosensor, clinical trials in the hospital setting and biosensor life.
Implantable Weight-Loss Device Receives CE Mark Approval
GI Dynamics has received European CE mark approval to commercialize a non-surgical device for the management of obesity and Type 2 diabetes.
[Company Profile] Pico-Tesla Magnetic Therapies
Pico-Tesla Magnetic Therapies, an emerging medical technology company based in Littleton, CO, has commenced a pilot study of its Magneceutical™ Therapy as a treatment for type 2 diabetes, the most common form of the disease.
Spherix Shares Rise on Promising Diabetes Drug Data
Shares in Spherix shot up by 77 percent after the biotechnology company announced preliminary Phase III results for its Type 2 diabetes drug candidate.
Covidien Launches Nationwide Type 2 Diabetes Campaign
The Our Resolution movement is focused around the discovery that gastric bypass surgery resolves diabetes in approximately 77 percent of morbidly obese patients.
NeuroSearch’s Tesofensine Advances to Phase III Testing
Yesterday, OneMedPlace reported on several companies that are developing anti-obesity drugs. Another name can be added to the list.
VIVUS’ Qnexa Shows Promise For Diabetics
VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.